KR20220041090A - 화합물의 염, 그 염의 결정형 및 그의 제조 방법 및 용도 - Google Patents

화합물의 염, 그 염의 결정형 및 그의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20220041090A
KR20220041090A KR1020227002390A KR20227002390A KR20220041090A KR 20220041090 A KR20220041090 A KR 20220041090A KR 1020227002390 A KR1020227002390 A KR 1020227002390A KR 20227002390 A KR20227002390 A KR 20227002390A KR 20220041090 A KR20220041090 A KR 20220041090A
Authority
KR
South Korea
Prior art keywords
cancer
crystalline form
fluoro
fumarate
diffraction peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227002390A
Other languages
English (en)
Korean (ko)
Inventor
레이 인
정린 야오
Original Assignee
간 앤 리 파마슈티칼스 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220041090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 filed Critical 간 앤 리 파마슈티칼스 컴퍼니, 리미티드
Publication of KR20220041090A publication Critical patent/KR20220041090A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227002390A 2019-06-21 2020-06-22 화합물의 염, 그 염의 결정형 및 그의 제조 방법 및 용도 Withdrawn KR20220041090A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
CN201910542355.6 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (1)

Publication Number Publication Date
KR20220041090A true KR20220041090A (ko) 2022-03-31

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002390A Withdrawn KR20220041090A (ko) 2019-06-21 2020-06-22 화합물의 염, 그 염의 결정형 및 그의 제조 방법 및 용도

Country Status (16)

Country Link
US (1) US20220168302A1 (cg-RX-API-DMAC7.html)
EP (1) EP3988546A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538076A (cg-RX-API-DMAC7.html)
KR (1) KR20220041090A (cg-RX-API-DMAC7.html)
CN (1) CN115708409B (cg-RX-API-DMAC7.html)
AR (1) AR119184A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020296048A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025944A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144546A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003438A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000502A2 (cg-RX-API-DMAC7.html)
IL (1) IL289231A (cg-RX-API-DMAC7.html)
MX (1) MX2022000051A (cg-RX-API-DMAC7.html)
PH (1) PH12021553151A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020253875A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202200964B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2024208265A1 (zh) * 2023-04-04 2024-10-10 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
WO2020253875A1 (zh) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
JP2022538076A (ja) 2022-08-31
US20220168302A1 (en) 2022-06-02
CN115708409B (zh) 2026-08-07
BR112021025944A2 (pt) 2022-02-08
PH12021553151A1 (en) 2022-07-25
IL289231A (en) 2022-02-01
CN115708409A (zh) 2023-02-21
CA3144546A1 (en) 2020-12-24
CL2021003438A1 (es) 2022-09-30
AR119184A1 (es) 2021-12-01
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
ZA202200964B (en) 2022-08-31
AU2020296048A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
KR102516745B1 (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
TW202327593A (zh) Kras抑制劑的多晶型物及其製備方法和用途
AU2016323399B2 (en) 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer
CN114981268A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
JP6905662B2 (ja) 置換キノリン化合物の結晶形およびその医薬組成物
KR20180070703A (ko) 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료에서의 이의 용도
CN111018846B (zh) 化合物晶型
KR102866403B1 (ko) 카세인 키나아제 1ε 억제제 및 약학 조성물 및 그 응용
JP2018533608A (ja) 置換キノリン化合物の結晶形およびその医薬組成物
TW202208375A (zh) ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
EP3988546A1 (en) Salts of compound, crystalline forms thereof, preparation method therefor and application thereof
WO2017153578A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP2020525469A (ja) 新規キノリノン化合物
KR20170095239A (ko) ＰＩ３Ｋβ 저해제로서의 이미다조피리다진 유도체
KR102768666B1 (ko) Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
CN109593102B (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
JP2022515622A (ja) チエノピリジノン化合物
WO2024114793A1 (zh) 泛素化特异性蛋白酶抑制剂盐型、晶型及其制备方法与应用
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
CN104119321B (zh) 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
EA039764B1 (ru) Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат
US11919898B2 (en) Crystal form of azaindole derivative and use thereof
RU2810113C2 (ru) Новые хинолиновые соединения
HK40040064A (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202